Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre Sells 10,000 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $61.75, for a total value of $617,500.00. Following the transaction, the senior vice president now directly owns 168,176 shares of the company’s stock, valued at approximately $10,384,868. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Halozyme Therapeutics Price Performance

HALO stock opened at $62.17 on Thursday. The company has a debt-to-equity ratio of 8.44, a quick ratio of 5.36 and a current ratio of 6.64. The firm has a market capitalization of $7.91 billion, a price-to-earnings ratio of 25.69, a PEG ratio of 0.56 and a beta of 1.27. The firm has a 50 day moving average price of $53.99 and a 200-day moving average price of $45.49. Halozyme Therapeutics, Inc. has a 52-week low of $32.83 and a 52-week high of $62.34.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.73 by $0.18. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The business had revenue of $231.40 million for the quarter, compared to the consensus estimate of $204.94 million. During the same period in the previous year, the company posted $0.68 earnings per share. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. Equities research analysts forecast that Halozyme Therapeutics, Inc. will post 3.66 EPS for the current fiscal year.

Analysts Set New Price Targets

HALO has been the topic of several research analyst reports. JPMorgan Chase & Co. reduced their target price on Halozyme Therapeutics from $53.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Morgan Stanley lifted their target price on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Piper Sandler downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their price target for the stock from $48.00 to $51.00 in a research note on Friday, June 7th. JMP Securities cut their price objective on Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 8th. Finally, The Goldman Sachs Group increased their target price on Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research report on Monday, July 22nd. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $59.44.

Institutional Trading of Halozyme Therapeutics

Several institutional investors have recently bought and sold shares of HALO. International Assets Investment Management LLC purchased a new position in Halozyme Therapeutics in the 4th quarter worth approximately $1,030,000. Federated Hermes Inc. increased its holdings in Halozyme Therapeutics by 176.0% during the fourth quarter. Federated Hermes Inc. now owns 459,369 shares of the biopharmaceutical company’s stock valued at $16,978,000 after buying an additional 292,926 shares during the last quarter. Handelsbanken Fonder AB raised its position in Halozyme Therapeutics by 930.9% in the fourth quarter. Handelsbanken Fonder AB now owns 246,069 shares of the biopharmaceutical company’s stock worth $9,095,000 after acquiring an additional 222,200 shares during the period. Duality Advisers LP boosted its stake in shares of Halozyme Therapeutics by 31.0% during the 4th quarter. Duality Advisers LP now owns 52,926 shares of the biopharmaceutical company’s stock worth $1,956,000 after acquiring an additional 12,521 shares during the last quarter. Finally, Parkside Financial Bank & Trust bought a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at $64,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.